Abeona Therapeutics to Present at the 28th Annual ROTH Conference

NEW YORK, NY and CLEVELAND, OH --(Marketwired - March 10, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President and CEO, Tim Miller, Ph.D., will be presenting an overview of the company at the 28^th Annual Roth Conference on Monday, March 14^th, 2016 at 2pm PST in The Salon 5 PINK Room at The Ritz Carlton in Laguna Nigel, CA.

Event: 28^th Annual ROTH Conference
Date: Monday, March 14^th, 2016
Time: 2:00pm PDT
Location: The Ritz Carlton in Laguna Nigel, CA.
Room: Salon 5 -- PINK Room
Webcast Link: http://wsw.com/webcast/roth30/abeo

• The presentation will be open to all interested investors through a live audio webcast accessible from http://wsw.com/webcast/roth30/abeo and an archived replay of the webcast will also be available for 90 days following the live presentation.

About ROTH: ROTH Capital, 28th Annual Conference, is one of the largest of its kind in the U.S. Following the success of previous year's events, the ROTH Conference, with close to 550 participating companies and over 4,000 attendees, will feature presentations from public and private companies in a variety of sectors. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.

About Abeona : Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.